Cipla slashes prices of three key cancer medicines

03 May 2012 Evaluate

Cipla has slashed its prices on three key cancer medicines by taking advantage of the economies of scale it has managed to get on the product. The entity has significantly dropped its prices on generic Sorafenib, used in advanced kidney cancer, from Rs 27,950 to Rs 6,840.

Sorafenib is the drug on which the Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of this drug, on the payment of a royalty to the innovator company, Bayer. Natco had pegged its price at about Rs 8,900, while Bayer’s price on its branded Sorafenib (Nexavar) is Rs 2.8 lakh.

The company has also reduced its prices on lung cancer drug Gestinib by 60%. Retail prices have come down from Rs 10,200 to Rs 4,250. The original drug is made by Astra Zeneca under the name Iressa.

The third drug that Cipla is dropping the prices is on brain tumour drug Temozolamide in three strengths. Schering makes the original drug. On the 20-mg pack of five, Cipla has been brought down the prices from Rs 1,875 to Rs 480; on the 100-mg strength prices are down from Rs 8,900 to Rs 2,400 and on the 250 mg it is down from Rs 20,250 to Rs 5,000.

Cipla Share Price

1541.00 -13.40 (-0.86%)
29-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1541.00
Lupin 2067.40
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...